Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Gene of MLL leukemia targeted dual-specific chimeric antigen receptor and application of MLL leukemia targeted dual-specific chimeric antigen receptor

A chimeric antigen receptor, bispecific technology, applied in the field of biomedicine, can solve the problems of decreased immunity and reduced quality of life of patients, and achieve the effects of reducing the killing effect, reducing the probability of escape, and reasonable molecular design

Active Publication Date: 2017-05-31
RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF3 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, since CD19 is a surface marker of B cells and is expressed in both normal B cells and B cell tumors, this treatment strategy will inevitably bring about a side effect of reducing normal B cells. There is a great degree of remission or complete cure, but long-term or even lifelong intravenous gamma globulin supplementation is required to avoid the decline in immunity caused by the reduction of B cells, which greatly reduces the quality of life of patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Gene of MLL leukemia targeted dual-specific chimeric antigen receptor and application of MLL leukemia targeted dual-specific chimeric antigen receptor
  • Gene of MLL leukemia targeted dual-specific chimeric antigen receptor and application of MLL leukemia targeted dual-specific chimeric antigen receptor
  • Gene of MLL leukemia targeted dual-specific chimeric antigen receptor and application of MLL leukemia targeted dual-specific chimeric antigen receptor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0041] The bispecific chimeric antigen receptor targeting MLL leukemia provided by the present invention consists of CD8leader, CD19scFv, linker, CD133scFv, hinge region and transmembrane region of CD8, CD28 intracellular signal region, 4-1BB intracellular signal region , CD3-zata intracellular signal region in series, its structure is as follows figure 1 Shown in (TanCAR(1linker)).

[0042] The nucleotide sequence of the gene encoding the bispecific chimeric antigen receptor targeting MLL leukemia is shown in SEQ ID NO.1, wherein 1-63 is CD8leader, 64-789 is CD19scFv, 790-804 is linker, 805-1536 was CD133scFv, 1537-1671 was CD8hinge, 1672-1743 was CD8transmember, 1744-1866 was CD28 intracellular domain, 1867-1992 was 4-1BB intracellular domain, 1993-2328 was CD3-zata domain.

[0043] (1), construction of pCDH-TanCAR(3linker), pCDH-TanCAR(2linker) and pCDH-TanCAR(1linker) plasmids

[0044] The present invention obtains the cDNA sequence encoding the heavy chain (VH) and ligh...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a gene of an MLL leukemia targeted dual-specific chimeric antigen receptor and an application of the MLL leukemia targeted dual-specific chimeric antigen receptor. The dual-specific chimeric antigen receptor disclosed by the invention can be used for specifically recognizing two kinds of tumor associated antigens, i.e., CD19 and CD133 on surfaces of MLL leukemia cells. The dual-specific chimeric antigen receptor is expressed through recombining a TanCAR molecule to a virus vector and carrying out T lymphocyte series transfection, dual positive tumor cells, i.e., the CD19 and the CD133 can be specifically recognized and killed, the kill effect on non-tumor cells is relieved, and the probability of escape of tumor antigens is lowered. The MLL leukemia cells can be specifically killed by TanCAR(1linker)-Jurkat in case of a relatively low effector-target ratio, and toxic or side effects less occur in subsequent clinical use, for example cytokine storm and neurotoxicity. The dual-specific chimeric antigen receptor disclosed by the invention can be applied to the treatment of MLL leukemia and is used for clearing in-vivo tumors from patients and prolonging lifetime of the patients.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a bispecific chimeric antigen receptor gene targeting MLL leukemia. Background technique [0002] The immune response mediated by tumor-specific T cells is the main means for the body to eliminate tumor cells. In a normal immune response, T cell activation requires two stimulating signals. Among them, the TCR-CD3 complex on the surface of T cells binds to antigen peptide-MHC molecules, providing the first signal for T cell activation and determining the killing specificity of T cells; the second signal is formed by T cells and antigen-presenting cells (APCs). or other co-stimulatory molecules on the cell surface. Tumor cells produce immune escape by down-regulating the expression of molecules involved in T cell recognition and antigen response, reducing immunogenicity, etc., so that the body's immune system cannot clear the tumor well. [0003] Studies have found that the s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00C12N15/62C12N15/867A61K35/17A61P35/02
CPCA61K35/17C07K14/7051C07K14/70517C07K14/70521C07K14/70578C07K16/2803C07K16/2896C07K2319/03C07K2319/33C12N15/86C12N2740/15043
Inventor 刘晗李丹孙燕朱守海葛茂林康婷胡雨田
Owner RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products